Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Naltrexone for Post-COVID Fatigue Syndrome
NCT05430152Phase 2Completed
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone in post-COVID-19 condition (PCC). Started Jan 2024; status: completed.
02
Drugs
naltrexone
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05430152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05430152.